BACKGROUND: Alveolar soft part sarcoma (ASPS) is a rare soft tissue tumor that usually affects young patients. A comprehensive retrospective review was performed of clinical presentation, treatment, outcome, and patterns of failure in a consecutive series of patients with localized or metastatic ASPS between 1975 and 2008. METHODS: Demographics, tumor sizes, sites and extent of disease, treatments provided, progression-free survival, and overall survival were evaluated. RESULTS: A total of 33 patients were identified. Preoperative imaging misdiagnosed a vascular malformation in three cases (9%), delaying treatment. The most common location of primary tumor was the thigh. The median diameter of the mass was 9 cm (range, 2-15 cm). The tumor was deeply located in most cases (78.7%). A R0 resection was obtained in 27 cases. Adjuvant radiotherapy was delivered in 12 cases, in 6 cases in association with chemotherapy; preoperative systemic chemotherapy was delivered in 4 cases, in the adjuvant setting in another 3 cases. Twenty-one (63.6%) of 33 patients exhibited metastases either at presentation (10 patients, 30.3%) or later. Metastatic sites included lymph nodes, lung, bone, and liver. Median overall follow-up was 72 months. Overall survival was 68.7% at 5 years and 53.4% at 10 years. Metastectomies were performed in 33% of metastatic cases (7 of 21 patients). CONCLUSIONS: Prognosis of ASPS is basically related to the characteristics of the disease and the quality of surgery. Overall, the occurrence of distant metastases is quite common, with a typical indolent course. New agents are eagerly needed to complement surgery to eradicate this disease.
BACKGROUND:Alveolar soft part sarcoma (ASPS) is a rare soft tissue tumor that usually affects young patients. A comprehensive retrospective review was performed of clinical presentation, treatment, outcome, and patterns of failure in a consecutive series of patients with localized or metastatic ASPS between 1975 and 2008. METHODS: Demographics, tumor sizes, sites and extent of disease, treatments provided, progression-free survival, and overall survival were evaluated. RESULTS: A total of 33 patients were identified. Preoperative imaging misdiagnosed a vascular malformation in three cases (9%), delaying treatment. The most common location of primary tumor was the thigh. The median diameter of the mass was 9 cm (range, 2-15 cm). The tumor was deeply located in most cases (78.7%). A R0 resection was obtained in 27 cases. Adjuvant radiotherapy was delivered in 12 cases, in 6 cases in association with chemotherapy; preoperative systemic chemotherapy was delivered in 4 cases, in the adjuvant setting in another 3 cases. Twenty-one (63.6%) of 33 patients exhibited metastases either at presentation (10 patients, 30.3%) or later. Metastatic sites included lymph nodes, lung, bone, and liver. Median overall follow-up was 72 months. Overall survival was 68.7% at 5 years and 53.4% at 10 years. Metastectomies were performed in 33% of metastatic cases (7 of 21 patients). CONCLUSIONS: Prognosis of ASPS is basically related to the characteristics of the disease and the quality of surgery. Overall, the occurrence of distant metastases is quite common, with a typical indolent course. New agents are eagerly needed to complement surgery to eradicate this disease.
Authors: Silvia Stacchiotti; Olivier Mir; Axel Le Cesne; Bruno Vincenzi; Alexander Fedenko; Robert G Maki; Neeta Somaiah; Shreyaskumar Patel; Mehedi Brahmi; Jean Y Blay; Kjetil Boye; Kirsten Sundby Hall; Hans Gelderblom; Nadia Hindi; Javier Martin-Broto; Hanna Kosela; Piotr Rutkowski; Antoine Italiano; Florence Duffaud; Eisuke Kobayashi; Paolo G Casali; Salvatore Provenzano; Akira Kawai Journal: Oncologist Date: 2017-07-28
Authors: John M Goldberg; David E Fisher; George D Demetri; Donna Neuberg; Stephen A Allsop; Catia Fonseca; Yukoh Nakazaki; David Nemer; Chandrajit P Raut; Suzanne George; Jeffrey A Morgan; Andrew J Wagner; Gordon J Freeman; Jerome Ritz; Cecilia Lezcano; Martin Mihm; Christine Canning; F Stephen Hodi; Glenn Dranoff Journal: Clin Cancer Res Date: 2015-03-24 Impact factor: 12.531
Authors: Patricia L Zadnik; Alp Yurter; Rosa DeLeon; Camilo A Molina; Mari L Groves; Edward McCarthy; Daniel M Sciubba Journal: Skeletal Radiol Date: 2013-10-04 Impact factor: 2.199